[Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs].
Concerning the current discussion about cardiovascular toxicity of the selective COX-2 inhibitors, recently advertised in the media as a new milestone in the management of pain, culminating in the market withdrawal of the preparations Vioxx (rofecoxib) in 2004 and Bextra (valdecoxib) in 2005, the classical NSAIDs are now spotlighted. How safe are the "well established" NSAIDs regarding adverse cardiovascular events? Long term studies now show a similar overall risk compared to the selective COX-2 inhibitors. The short lasting perioperative administration of both drug classes are still indicated. However, even here they should be only used after a systematic risk-calculation and not on a routine basis.
Lange
Henning
H
Klinik für Anästhesie und Intensivtherapie, Uniklinikum Giessen, Standort Marburg, Germany. Henning.Lange@med.uni-marburg.de
Eberhart
Leopold
L
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000639:trends*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D006801:Humans; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors